Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms

被引：0
|
作者：
Ryo Ariyasu
Noriko Yanagitani
Kenichi Tadokoro
Toshikazu Yamaguchi
Ken Uchibori
Satoru Kitazono
Naoya Fujita
Ryohei Katayama
Makoto Nishio
机构：
[1] The Cancer Institute Hospital,Department of Thoracic Medical Oncology
[2] Japanese Foundation for Cancer Research,Cancer Chemotherapy Center
[3] BML,undefined
[4] INC,undefined
[5] Japanese Foundation for Cancer Research,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
deletion polymorphism; single nucleotide polymorphism; Non-small cell lung cancer; EGFR-TKI;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：517 / 525
页数：8
相关论文
共 50 条
  • [41] Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes
    Lorraine Dalens
    Julie Niogret
    Corentin Richard
    Sandy Chevrier
    Pascal Foucher
    Bruno Coudert
    Aurélie Lagrange
    Laure Favier
    Virginie Westeel
    Stefano Kim
    Olivier Adotevi
    Caroline Chapusot
    Laurent Martin
    Laurent Arnould
    Courèche-Guillaume Kaderbhai
    Romain Boidot
    Molecular Cancer, 22
  • [42] Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
    Li, Xingyuan
    Huang, Huayan
    Sun, Yingjia
    Jiang, Qing
    Yu, Yongfeng
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [43] EGFR Inhibitors Plus Bevacizumab Are Superior Compared to EGFR Inhibitor Monotherapy in Advanced EGFR plus NSCLC Patients with BIM Deletions
    Cardona, A. F.
    Arrieta, O. G.
    Ruiz-Patino, A.
    Zatarain Barron, Z. L.
    Rojas, L. L.
    Corrales, L.
    Martin, C.
    Barron, F.
    Sotelo, C.
    Rodriguez, J.
    Ricaurte, L.
    Avila, J.
    Mayorga, D.
    Archila, P.
    Otero, J.
    Freitas, H.
    Cordeiro De Lima, V.
    Mas, L.
    Carranza, H.
    Vargas, C.
    Rosell, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S579 - S579
  • [44] Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
    Xia, Jinjing
    Bai, Hao
    Yan, Bo
    Li, Rong
    Shao, Minhua
    Xiong, Liwen
    Han, Baohui
    ONCOTARGET, 2017, 8 (65) : 108522 - 108533
  • [45] Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors
    Woo, Hyun Sun
    Ahn, Hee Kyung
    Lee, Ha Yeon
    Park, Inkeun
    Kim, Young Saing
    Hong, Junshik
    Sym, Sun Jin
    Park, Jinny
    Lee, Jae Hoon
    Shin, Dong Bok
    Cho, Eun Kyung
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1311 - 1315
  • [46] Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib
    Masood, Ashiq
    Kancha, Rama Krishna
    Subramanian, Janakiraman
    SEMINARS IN ONCOLOGY, 2019, 46 (03) : 271 - 283
  • [47] Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors
    Hyun Sun Woo
    Hee Kyung Ahn
    Ha Yeon Lee
    Inkeun Park
    Young Saing Kim
    Junshik Hong
    Sun Jin Sym
    Jinny Park
    Jae Hoon Lee
    Dong Bok Shin
    Eun Kyung Cho
    Investigational New Drugs, 2014, 32 : 1311 - 1315
  • [48] BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations
    Cardona, Andres F.
    Rojas, Leonardo
    Wills, Beatriz
    Arrieta, Oscar
    Carranza, Hernan
    Vargas, Carlos
    Otero, Jorge
    Corrales-Rodriguez, Luis
    Martin, Claudio
    Reguart, Noemi
    Archila, Pilar
    Rodriguez, July
    Cuello, Mauricio
    Ortiz, Carlos
    Franco, Sandra
    Rolfo, Christian
    Rosell, Rafael
    ONCOTARGET, 2016, 7 (42) : 68933 - 68942
  • [49] Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases
    Flippot, R.
    Auclin, E.
    Biondani, P.
    Le Rhun, E.
    Adam, J.
    Planchard, D.
    Caramella, C.
    Le Pechoux, C.
    Lacroix, L.
    Gazzah, A.
    Mezquita, L.
    Besse, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S467 - S467
  • [50] Inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase: similarity and differences
    Lokiec, F.
    Douillard, J. -Y.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2011, 67 : S15 - S19
12345